Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,366 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Tamura K, Mukai H, Naito Y, Yonemori K, Kodaira M, Tanabe Y, Yamamoto N, Osera S, Sasaki M, Mori Y, Hashigaki S, Nagasawa T, Umeyama Y, Yoshino T. Tamura K, et al. Among authors: yamamoto n. Cancer Sci. 2016 Jun;107(6):755-63. doi: 10.1111/cas.12932. Epub 2016 May 11. Cancer Sci. 2016. PMID: 26991823 Free PMC article. Clinical Trial.
Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer.
Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M, Saijo N. Sekine I, et al. Among authors: yamamoto n. Cancer Sci. 2004 Aug;95(8):691-5. doi: 10.1111/j.1349-7006.2004.tb03331.x. Cancer Sci. 2004. PMID: 15298734 Free PMC article. Clinical Trial.
Severe drug toxicity associated with a single-nucleotide polymorphism of the cytidine deaminase gene in a Japanese cancer patient treated with gemcitabine plus cisplatin.
Yonemori K, Ueno H, Okusaka T, Yamamoto N, Ikeda M, Saijo N, Yoshida T, Ishii H, Furuse J, Sugiyama E, Kim SR, Kikura-Hanajiri R, Hasegawa R, Saito Y, Ozawa S, Kaniwa N, Sawada J. Yonemori K, et al. Among authors: yamamoto n. Clin Cancer Res. 2005 Apr 1;11(7):2620-4. doi: 10.1158/1078-0432.CCR-04-1497. Clin Cancer Res. 2005. PMID: 15814642 Clinical Trial.
Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.
Yamada Y, Tamura T, Yamamoto N, Shimoyama T, Ueda Y, Murakami H, Kusaba H, Kamiya Y, Saka H, Tanigawara Y, McGovren JP, Natsumeda Y. Yamada Y, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2006 Aug;58(2):173-82. doi: 10.1007/s00280-005-0149-6. Epub 2005 Nov 25. Cancer Chemother Pharmacol. 2006. PMID: 16308697 Clinical Trial.
Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors.
Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y, Takayama K, Tokudome T, Klimovsky J, Tamura T. Shimizu T, et al. Among authors: yamamoto n. Cancer Chemother Pharmacol. 2008 Apr;61(5):751-8. doi: 10.1007/s00280-007-0530-8. Epub 2007 Jun 27. Cancer Chemother Pharmacol. 2008. PMID: 17594093 Clinical Trial.
6,366 results